Discover the alternative term for Jardiance, a medication commonly used in the treatment of various medical conditions.

If you work in the medical field, you may come across the term “jardiance” when talking about diabetes treatments. However, it is important to note that “jardiance” is the brand name of a medication that is prescribed to treat type 2 diabetes. The generic name for this medication is empiria. The generic name of this medication is empagliflozin. Empagliflozin belongs to a class of medications known as sodium-glucose cotransporter 2 (SGLT2) inhibitors.

1. Empagliflozin is primarily used to lower blood sugar levels in adults with type 2 diabetes.
2. This medication works by increasing the excretion of glucose in the urine, which helps reduce blood glucose levels.
3. Empagliflozin is usually prescribed along with diet and exercise to improve glycemic control.

Important information:

It is crucial that you inform your healthcare provider of any pre-existing medical conditions or medications you are currently taking before starting treatment with empagliflozin.

Empagliflozin may cause side effects such as genital yeast infections, urinary tract infections, low blood pressure, and ketoacidosis. If you experience any of these symptoms, it is important to seek medical attention immediately.

It is important to remember that empagliflozin should always be taken as prescribed and under the supervision of a healthcare professional. This article provides a brief overview of empagliflozin, another name for the medication commonly recognized as jardiance.

Understanding Jardiance: What is it and how does it work?

Jardiance mechanism of action: Empagliflozin, the active substance in Jardiance, inhibits SGLT2 proteins in the proximal renal tubules. These proteins are responsible for reabsorbing glucose from the urine into the bloodstream. By inhibiting SGLT2, Jardiance prevents glucose reabsorption and increases its excretion through urine.

Jardiance increases the excretion of glucose in the urine, thereby reducing blood glucose levels in people with type 2 diabetes.

Jardiance Benefits: In addition to its glucose-lowering effects, Jardiance has been shown to have other positive effects in people with type 2 diabetes. Clinical studies have shown that Jardiance can help reduce body weight, systolic blood pressure, and heart rate. cardiovascular risk in patients with established cardiovascular disease.

Jardiance Precautions and Side Effects: Although Jardiance is generally well tolerated, it is important to be aware of possible side effects. The most common side effects include an increased risk of urinary tract infections, genital yeast infections, and an increased chance of dehydration. It is crucial that patients taking Jardiance stay hydrated and maintain proper personal hygiene to prevent these side effects.

Jardiance synonyms: Alternative names for the medication

Below is a list of alternative names for Jardiance:

• Empagliflozin
• Metfogamma
• Invokana
• Megalotect
• Glenkontrol

Jardiance is known by several synonyms, such as Empagliflozin. This medication is primarily used to treat type 2 diabetes by lowering blood sugar levels. Another alternative name of Jardiance is Metfogamma, which is also prescribed to control diabetes mellitus.

In addition to Empagliflozin and Metfogamma, Jardiance is sometimes called Invokana, Megalotect, or Glenkontrol. It is important for healthcare professionals to know these names, as patients may describe the medication by different names. By recognizing and understanding the various synonyms for Jardiance, healthcare professionals can effectively communicate and address patients’ medication needs.

Empagliflozin: The active ingredient in Jardiance

One of the main mechanisms of action of empagliflozin is its ability to inhibit the SGLT-2 protein, mainly responsible for glucose reabsorption in the kidneys. By inhibiting this protein, empagliflozin promotes the excretion of excess glucose through urine, thus reducing blood sugar levels.

Important information:

• Empagliflozin should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
• Among the most common side effects of empagliflozin are urinary and genital infections, increased urination, and high blood pressure.
• It is important to regularly control the renal function while taking packing, since it can cause acute renal injury.

Pagliflozine has proven to be an effective complementary treatment in the treatment of type 2 diabetes mellitus, especially in patients who do not achieve adequate glycemic control only with diet and exercise. The drug offers an additional approach to control blood sugar levels by acting on the reabsorption process of glucose. However, it is crucial to take into account the possible side effects and contraindications associated with the pickery, and patients should always consult with their doctor before starting or adjusting their treatment regime.

Exploring the benefits of Jardiance’s alternative name

One of the main benefits of Jardiance, or Pagliflozine, is its ability to reduce the risk of cardiovascular events in patients with type 2. Clinical trials have shown that Jardiance can significantly reduce the risk of cardiovascular death, no n-mortal myocardial infarctions andNo n-mortal stroke in people with established cardiovascular disease. This important finding has led to the inclusion of Jardiance in the treatment of type 2 diabetes in patients with high risk of cardiovascular complications.

The benefits of Jardiance can be summarized as follows:

• Effective glucose reduction properties by inhibition of renal glucose reabsorption.
• Reduction of cardiovascular events, including cardiovascular death, myocardial infarctions and strokes
• BENEFITS IN WEIGHT LOSS Due to the increase in urinary glucose excretion
• Reducing effects of blood pressure
• Renal protective effects, including a decrease in the progression of albuminuria

Important note: Jardiance, or Pagliflozine, should not be used in patients with diabetes type 1 or diabetic ketoacidosis. It can also increase the risk of genital icing and urinary tract infections. Patients should always consult their doctor before starting any new medication.

Comparing Jardiance to other SGLT2 inhibitors

When comparing Jardiance to other SGLT2 inhibitors, it is essential to consider its efficacy, safety profile, and additional benefits. A frequently prescribed medication in the same class is Invokana, which shares a similar mechanism of action with Jardiance. Both Jardiance and Invokana have shown significant reductions in glycated hemoglobin (HbA1c) levels, fasting plasma glucose (FPG) levels and body weight when used alone or in combination with other antidiabetic agents.

Both Jardiance and Invokana are effective in lowering HbA1c levels, and Jardiance may offer additional cardiovascular benefits.

Although Jardiance is generally well tolerated, it is important to monitor for genitourinary infections and the rare occurrence of ketoacidosis in certain patients.

Potential Side Effects of Jardiance and its Alternative Name

Possible side effects:

1. Genital yeast infections: One of the most common side effects reported by patients taking Jardiance is genital yeast infections. This occurs more frequently in women and can lead to itching, burning or discomfort in the genital area. It is important to note that yeast infections can also occur in men.
2. Urinary tract infections (UTI): Another possible side effect of Jardiance is an increased risk of urinary tract infections. UTIs can cause symptoms such as pain or burning sensation when urinating, frequent urination, and cloudy or bloody urine.
3. Low blood sugar levels (hypoglycemia): Although Jardiance is designed to lower blood sugar levels, in some cases it can cause blood sugar levels to drop too low. This can cause symptoms such as dizziness, confusion, sweating, and weakness.

“It is important that patients taking Jardiance are aware of these possible side effects and seek medical attention if they experience any adverse reactions. Doctors should carefully consider the risks and benefits of Jardiance before prescribing it to their patients.”

Although Jardiance is a commonly prescribed medication, there is also an alternative name for this drug. This is empagliflozin. Both Jardiance and empagliflozin contain the same active ingredient and act in a similar way. Doctors may prescribe Jardiance or empagliflozin based on factors such as availability and patient preferences.

Using Jardiance’s alternative name when discussing with healthcare providers

Jardiance, whose alternative name is empagliflozin, belongs to a class of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors. These medications block glucose reabsorption by the kidneys, which increases glucose excretion in the urine and lowers blood sugar levels. Empagliflozin has been shown to significantly reduce the risk of cardiovascular events, including myocardial infarction and stroke, in people with type 2 diabetes and established cardiovascular disease.

Empagliflozin, also known by its brand name Jardiance, is a very effective medication for the treatment of type 2 diabetes.

When discussing the use of empagliflozin with healthcare professionals, it is important to provide accurate information and use the alternative name, Jardiance, to avoid any confusion. Healthcare professionals are well aware of the different names of medications and using specific names can facilitate better understanding and communication. By using the alternative name of Jardiance, patients can ensure that their healthcare team knows the medication they are talking about and can provide appropriate guidance and recommendations.

• Empagliflozin, or Jardiance, has been shown to be effective in lowering blood sugar levels in people with type 2 diabetes. This medication comes in tablet form and can be taken orally.
• This medication comes in tablet form and is usually taken once a day.
• Before starting empagliflozin, patients should inform their doctor of any other medications they are taking to avoid possible interactions.

LikeDislike

Author of the article

Dr.Greenblatt M.

Medical oncologist at the Robert Larner College of Medicine, MD, at the University of Vermont